nodes	percent_of_prediction	percent_of_DWPC	metapath
Fingolimod—CYP2E1—Etoposide—testicular cancer	0.0374	0.3	CbGbCtD
Fingolimod—CYP4F12—seminal vesicle—testicular cancer	0.0313	0.0946	CbGeAlD
Fingolimod—S1PR3—gonad—testicular cancer	0.027	0.0816	CbGeAlD
Fingolimod—CYP3A4—Ifosfamide—testicular cancer	0.0237	0.19	CbGbCtD
Fingolimod—SPHK1—gonad—testicular cancer	0.0235	0.0711	CbGeAlD
Fingolimod—S1PR3—female gonad—testicular cancer	0.0219	0.0663	CbGeAlD
Fingolimod—S1PR4—lymph node—testicular cancer	0.0202	0.061	CbGeAlD
Fingolimod—CYP2D6—Vinblastine—testicular cancer	0.0198	0.159	CbGbCtD
Fingolimod—S1PR3—testis—testicular cancer	0.0194	0.0588	CbGeAlD
Fingolimod—S1PR1—female gonad—testicular cancer	0.0193	0.0584	CbGeAlD
Fingolimod—SPHK1—female gonad—testicular cancer	0.0191	0.0578	CbGeAlD
Fingolimod—CYP4F12—female gonad—testicular cancer	0.0184	0.0555	CbGeAlD
Fingolimod—S1PR1—testis—testicular cancer	0.0171	0.0518	CbGeAlD
Fingolimod—SPHK1—testis—testicular cancer	0.017	0.0513	CbGeAlD
Fingolimod—S1PR5—lymph node—testicular cancer	0.017	0.0513	CbGeAlD
Fingolimod—CYP4F12—testis—testicular cancer	0.0163	0.0493	CbGeAlD
Fingolimod—S1PR3—lymph node—testicular cancer	0.0141	0.0426	CbGeAlD
Fingolimod—CYP3A4—Vinblastine—testicular cancer	0.0126	0.101	CbGbCtD
Fingolimod—CYP4F2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.0124	0.102	CbGpPWpGaD
Fingolimod—S1PR1—lymph node—testicular cancer	0.0124	0.0376	CbGeAlD
Fingolimod—SPHK1—lymph node—testicular cancer	0.0123	0.0372	CbGeAlD
Fingolimod—CYP2D6—Doxorubicin—testicular cancer	0.0121	0.0975	CbGbCtD
Fingolimod—CYP4F12—lymph node—testicular cancer	0.0118	0.0357	CbGeAlD
Fingolimod—Lymphopenia—Chlorambucil—testicular cancer	0.0116	0.0273	CcSEcCtD
Fingolimod—CYP3A4—Etoposide—testicular cancer	0.0113	0.0909	CbGbCtD
Fingolimod—Non-Hodgkin's lymphoma—Ifosfamide—testicular cancer	0.0112	0.0265	CcSEcCtD
Fingolimod—Lymphoma—Ifosfamide—testicular cancer	0.0112	0.0265	CcSEcCtD
Fingolimod—CYP3A4—Doxorubicin—testicular cancer	0.00773	0.062	CbGbCtD
Fingolimod—S1PR4—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00726	0.0598	CbGpPWpGaD
Fingolimod—S1PR3—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00699	0.0575	CbGpPWpGaD
Fingolimod—S1PR5—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00699	0.0575	CbGpPWpGaD
Fingolimod—S1PR1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00635	0.0522	CbGpPWpGaD
Fingolimod—S1PR4—GPCR ligand binding—INSL3—testicular cancer	0.00553	0.0455	CbGpPWpGaD
Fingolimod—CYP4F12—Biological oxidations—HPGDS—testicular cancer	0.00536	0.0441	CbGpPWpGaD
Fingolimod—S1PR5—GPCR ligand binding—INSL3—testicular cancer	0.00532	0.0438	CbGpPWpGaD
Fingolimod—S1PR3—GPCR ligand binding—INSL3—testicular cancer	0.00532	0.0438	CbGpPWpGaD
Fingolimod—Lymphoma—Methotrexate—testicular cancer	0.0053	0.0125	CcSEcCtD
Fingolimod—CYP2E1—seminal vesicle—testicular cancer	0.00527	0.016	CbGeAlD
Fingolimod—Herpes zoster—Ifosfamide—testicular cancer	0.0052	0.0123	CcSEcCtD
Fingolimod—S1PR1—GPCR ligand binding—INSL3—testicular cancer	0.00483	0.0398	CbGpPWpGaD
Fingolimod—CYP4F2—Biological oxidations—HPGDS—testicular cancer	0.00462	0.0381	CbGpPWpGaD
Fingolimod—Infection—Carboplatin—testicular cancer	0.00408	0.00964	CcSEcCtD
Fingolimod—Cerebrovascular accident—Vinblastine—testicular cancer	0.00402	0.0095	CcSEcCtD
Fingolimod—Liver injury—Cisplatin—testicular cancer	0.00401	0.00948	CcSEcCtD
Fingolimod—Cerebrovascular accident—Bleomycin—testicular cancer	0.0034	0.00802	CcSEcCtD
Fingolimod—Lymphopenia—Epirubicin—testicular cancer	0.00339	0.00801	CcSEcCtD
Fingolimod—Pneumonia—Chlorambucil—testicular cancer	0.00333	0.00787	CcSEcCtD
Fingolimod—Lymphopenia—Doxorubicin—testicular cancer	0.00314	0.00741	CcSEcCtD
Fingolimod—S1PR4—GPCR downstream signaling—INSL3—testicular cancer	0.00313	0.0257	CbGpPWpGaD
Fingolimod—Depression—Vinblastine—testicular cancer	0.00303	0.00715	CcSEcCtD
Fingolimod—S1PR5—GPCR downstream signaling—INSL3—testicular cancer	0.00301	0.0248	CbGpPWpGaD
Fingolimod—S1PR3—GPCR downstream signaling—INSL3—testicular cancer	0.00301	0.0248	CbGpPWpGaD
Fingolimod—Liver function test abnormal—Dactinomycin—testicular cancer	0.00286	0.00677	CcSEcCtD
Fingolimod—S1PR4—Signaling by GPCR—INSL3—testicular cancer	0.00284	0.0234	CbGpPWpGaD
Fingolimod—Aspartate aminotransferase increased—Dactinomycin—testicular cancer	0.00279	0.0066	CcSEcCtD
Fingolimod—CYP2E1—testis—testicular cancer	0.00275	0.00831	CbGeAlD
Fingolimod—S1PR3—Signaling by GPCR—INSL3—testicular cancer	0.00273	0.0225	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—INSL3—testicular cancer	0.00273	0.0225	CbGpPWpGaD
Fingolimod—S1PR1—GPCR downstream signaling—INSL3—testicular cancer	0.00273	0.0225	CbGpPWpGaD
Fingolimod—Cardiac arrest—Ifosfamide—testicular cancer	0.0027	0.00639	CcSEcCtD
Fingolimod—Alopecia—Chlorambucil—testicular cancer	0.00263	0.00621	CcSEcCtD
Fingolimod—Weight decreased—Bleomycin—testicular cancer	0.0026	0.00615	CcSEcCtD
Fingolimod—Pneumonia—Bleomycin—testicular cancer	0.00258	0.00609	CcSEcCtD
Fingolimod—Cerebrovascular accident—Cisplatin—testicular cancer	0.0025	0.00591	CcSEcCtD
Fingolimod—S1PR1—Signaling by GPCR—INSL3—testicular cancer	0.00248	0.0204	CbGpPWpGaD
Fingolimod—Herpes zoster—Methotrexate—testicular cancer	0.00246	0.00582	CcSEcCtD
Fingolimod—CYP2D6—female gonad—testicular cancer	0.00245	0.00742	CbGeAlD
Fingolimod—Alopecia—Vinblastine—testicular cancer	0.00241	0.00569	CcSEcCtD
Fingolimod—Pneumonia—Dactinomycin—testicular cancer	0.00241	0.00568	CcSEcCtD
Fingolimod—Leukopenia—Chlorambucil—testicular cancer	0.00232	0.00548	CcSEcCtD
Fingolimod—Herpes zoster—Epirubicin—testicular cancer	0.0023	0.00544	CcSEcCtD
Fingolimod—Aspartate aminotransferase increased—Cisplatin—testicular cancer	0.00221	0.00522	CcSEcCtD
Fingolimod—Pneumonia—Ifosfamide—testicular cancer	0.0022	0.00521	CcSEcCtD
Fingolimod—Infestation—Ifosfamide—testicular cancer	0.00219	0.00518	CcSEcCtD
Fingolimod—Infestation NOS—Ifosfamide—testicular cancer	0.00219	0.00518	CcSEcCtD
Fingolimod—CYP2D6—testis—testicular cancer	0.00218	0.00658	CbGeAlD
Fingolimod—Cardiac arrest—Etoposide—testicular cancer	0.00214	0.00505	CcSEcCtD
Fingolimod—Herpes zoster—Doxorubicin—testicular cancer	0.00213	0.00504	CcSEcCtD
Fingolimod—Leukopenia—Vinblastine—testicular cancer	0.00212	0.00502	CcSEcCtD
Fingolimod—Infection—Chlorambucil—testicular cancer	0.0021	0.00496	CcSEcCtD
Fingolimod—Liver injury—Epirubicin—testicular cancer	0.00206	0.00487	CcSEcCtD
Fingolimod—Hypertension—Vinblastine—testicular cancer	0.00205	0.00484	CcSEcCtD
Fingolimod—Alopecia—Bleomycin—testicular cancer	0.00203	0.00481	CcSEcCtD
Fingolimod—Bradycardia—Ifosfamide—testicular cancer	0.002	0.00473	CcSEcCtD
Fingolimod—Alanine aminotransferase increased—Etoposide—testicular cancer	0.00198	0.00468	CcSEcCtD
Fingolimod—Hepatic enzyme increased—Methotrexate—testicular cancer	0.00196	0.00463	CcSEcCtD
Fingolimod—Connective tissue disorder—Ifosfamide—testicular cancer	0.00193	0.00457	CcSEcCtD
Fingolimod—Liver injury—Doxorubicin—testicular cancer	0.00191	0.00451	CcSEcCtD
Fingolimod—Alopecia—Dactinomycin—testicular cancer	0.0019	0.00448	CcSEcCtD
Fingolimod—Eye disorder—Ifosfamide—testicular cancer	0.00184	0.00434	CcSEcCtD
Fingolimod—Cardiac disorder—Ifosfamide—testicular cancer	0.00183	0.00431	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.00182	0.00431	CcSEcCtD
Fingolimod—Fatigue—Chlorambucil—testicular cancer	0.00182	0.0043	CcSEcCtD
Fingolimod—Leukopenia—Bleomycin—testicular cancer	0.00179	0.00424	CcSEcCtD
Fingolimod—Atrioventricular block—Epirubicin—testicular cancer	0.00179	0.00422	CcSEcCtD
Fingolimod—Angiopathy—Ifosfamide—testicular cancer	0.00178	0.00422	CcSEcCtD
Fingolimod—CYP4F2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.00178	0.0146	CbGpPWpGaD
Fingolimod—Mediastinal disorder—Ifosfamide—testicular cancer	0.00177	0.00419	CcSEcCtD
Fingolimod—Cough—Bleomycin—testicular cancer	0.00175	0.00413	CcSEcCtD
Fingolimod—Pneumonia—Etoposide—testicular cancer	0.00174	0.00411	CcSEcCtD
Fingolimod—Paraesthesia—Vinblastine—testicular cancer	0.00174	0.00411	CcSEcCtD
Fingolimod—Alopecia—Ifosfamide—testicular cancer	0.00174	0.00411	CcSEcCtD
Fingolimod—Infestation—Etoposide—testicular cancer	0.00173	0.00409	CcSEcCtD
Fingolimod—Infestation NOS—Etoposide—testicular cancer	0.00173	0.00409	CcSEcCtD
Fingolimod—Bradycardia—Cisplatin—testicular cancer	0.00173	0.00408	CcSEcCtD
Fingolimod—Mental disorder—Ifosfamide—testicular cancer	0.00172	0.00407	CcSEcCtD
Fingolimod—S1PR4—Signaling Pathways—INSL3—testicular cancer	0.00168	0.0138	CbGpPWpGaD
Fingolimod—Leukopenia—Dactinomycin—testicular cancer	0.00167	0.00395	CcSEcCtD
Fingolimod—Connective tissue disorder—Cisplatin—testicular cancer	0.00167	0.00394	CcSEcCtD
Fingolimod—Atrioventricular block—Doxorubicin—testicular cancer	0.00165	0.00391	CcSEcCtD
Fingolimod—Infection—Bleomycin—testicular cancer	0.00162	0.00384	CcSEcCtD
Fingolimod—S1PR5—Signaling Pathways—INSL3—testicular cancer	0.00161	0.0133	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—INSL3—testicular cancer	0.00161	0.0133	CbGpPWpGaD
Fingolimod—Vision blurred—Ifosfamide—testicular cancer	0.00161	0.00381	CcSEcCtD
Fingolimod—Eye disorder—Cisplatin—testicular cancer	0.00158	0.00374	CcSEcCtD
Fingolimod—Cardiac disorder—Cisplatin—testicular cancer	0.00157	0.00372	CcSEcCtD
Fingolimod—Leukopenia—Ifosfamide—testicular cancer	0.00153	0.00362	CcSEcCtD
Fingolimod—Mediastinal disorder—Cisplatin—testicular cancer	0.00153	0.00361	CcSEcCtD
Fingolimod—Hypotension—Bleomycin—testicular cancer	0.00153	0.00361	CcSEcCtD
Fingolimod—SPHK1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.00153	0.0126	CbGpPWpGaD
Fingolimod—Asthenia—Chlorambucil—testicular cancer	0.00152	0.00358	CcSEcCtD
Fingolimod—Infection—Dactinomycin—testicular cancer	0.00152	0.00358	CcSEcCtD
Fingolimod—Palpitations—Ifosfamide—testicular cancer	0.00151	0.00358	CcSEcCtD
Fingolimod—Alopecia—Cisplatin—testicular cancer	0.0015	0.00354	CcSEcCtD
Fingolimod—Pruritus—Chlorambucil—testicular cancer	0.00149	0.00353	CcSEcCtD
Fingolimod—Cough—Ifosfamide—testicular cancer	0.00149	0.00353	CcSEcCtD
Fingolimod—Hypertension—Ifosfamide—testicular cancer	0.00148	0.00349	CcSEcCtD
Fingolimod—Paraesthesia—Bleomycin—testicular cancer	0.00147	0.00347	CcSEcCtD
Fingolimod—S1PR1—Signaling Pathways—INSL3—testicular cancer	0.00147	0.0121	CbGpPWpGaD
Fingolimod—Dyspnoea—Bleomycin—testicular cancer	0.00146	0.00344	CcSEcCtD
Fingolimod—Eye disorder—Etoposide—testicular cancer	0.00145	0.00343	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00145	0.00342	CcSEcCtD
Fingolimod—Diarrhoea—Chlorambucil—testicular cancer	0.00145	0.00342	CcSEcCtD
Fingolimod—Cardiac disorder—Etoposide—testicular cancer	0.00144	0.00341	CcSEcCtD
Fingolimod—Angiopathy—Etoposide—testicular cancer	0.00141	0.00333	CcSEcCtD
Fingolimod—Eczema—Epirubicin—testicular cancer	0.0014	0.00331	CcSEcCtD
Fingolimod—Mediastinal disorder—Etoposide—testicular cancer	0.0014	0.00331	CcSEcCtD
Fingolimod—Eye pain—Epirubicin—testicular cancer	0.00139	0.00329	CcSEcCtD
Fingolimod—Vision blurred—Cisplatin—testicular cancer	0.00139	0.00329	CcSEcCtD
Fingolimod—Asthenia—Vinblastine—testicular cancer	0.00139	0.00328	CcSEcCtD
Fingolimod—Infection—Ifosfamide—testicular cancer	0.00139	0.00328	CcSEcCtD
Fingolimod—Alopecia—Etoposide—testicular cancer	0.00137	0.00324	CcSEcCtD
Fingolimod—Cerebrovascular accident—Methotrexate—testicular cancer	0.00137	0.00324	CcSEcCtD
Fingolimod—Nervous system disorder—Ifosfamide—testicular cancer	0.00137	0.00324	CcSEcCtD
Fingolimod—Skin disorder—Ifosfamide—testicular cancer	0.00136	0.00321	CcSEcCtD
Fingolimod—Diarrhoea—Vinblastine—testicular cancer	0.00132	0.00313	CcSEcCtD
Fingolimod—Leukopenia—Cisplatin—testicular cancer	0.00132	0.00312	CcSEcCtD
Fingolimod—Fatigue—Dactinomycin—testicular cancer	0.00131	0.00311	CcSEcCtD
Fingolimod—Back pain—Etoposide—testicular cancer	0.00131	0.00309	CcSEcCtD
Fingolimod—Hypotension—Ifosfamide—testicular cancer	0.00131	0.00309	CcSEcCtD
Fingolimod—SPHK1—Signaling Pathways—INSL3—testicular cancer	0.0013	0.0107	CbGpPWpGaD
Fingolimod—Eczema—Doxorubicin—testicular cancer	0.0013	0.00306	CcSEcCtD
Fingolimod—Eye pain—Doxorubicin—testicular cancer	0.00129	0.00305	CcSEcCtD
Fingolimod—Cerebrovascular accident—Epirubicin—testicular cancer	0.00128	0.00304	CcSEcCtD
Fingolimod—Dizziness—Vinblastine—testicular cancer	0.00128	0.00303	CcSEcCtD
Fingolimod—Paraesthesia—Ifosfamide—testicular cancer	0.00125	0.00297	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00125	0.00295	CcSEcCtD
Fingolimod—Dyspnoea—Ifosfamide—testicular cancer	0.00125	0.00294	CcSEcCtD
Fingolimod—Liver function test abnormal—Methotrexate—testicular cancer	0.00124	0.00293	CcSEcCtD
Fingolimod—Migraine—Epirubicin—testicular cancer	0.00124	0.00293	CcSEcCtD
Fingolimod—Headache—Vinblastine—testicular cancer	0.00121	0.00287	CcSEcCtD
Fingolimod—Leukopenia—Etoposide—testicular cancer	0.00121	0.00286	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00121	0.00285	CcSEcCtD
Fingolimod—Fatigue—Ifosfamide—testicular cancer	0.0012	0.00285	CcSEcCtD
Fingolimod—Cardiac arrest—Epirubicin—testicular cancer	0.0012	0.00283	CcSEcCtD
Fingolimod—Infection—Cisplatin—testicular cancer	0.0012	0.00283	CcSEcCtD
Fingolimod—Cerebrovascular accident—Doxorubicin—testicular cancer	0.00119	0.00281	CcSEcCtD
Fingolimod—Nervous system disorder—Cisplatin—testicular cancer	0.00118	0.00279	CcSEcCtD
Fingolimod—Cough—Etoposide—testicular cancer	0.00118	0.00279	CcSEcCtD
Fingolimod—Asthenia—Bleomycin—testicular cancer	0.00117	0.00277	CcSEcCtD
Fingolimod—Skin disorder—Cisplatin—testicular cancer	0.00117	0.00277	CcSEcCtD
Fingolimod—Hypertension—Etoposide—testicular cancer	0.00117	0.00276	CcSEcCtD
Fingolimod—Liver function test abnormal—Epirubicin—testicular cancer	0.00116	0.00275	CcSEcCtD
Fingolimod—Pruritus—Bleomycin—testicular cancer	0.00116	0.00273	CcSEcCtD
Fingolimod—Migraine—Doxorubicin—testicular cancer	0.00115	0.00271	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00114	0.0027	CcSEcCtD
Fingolimod—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.00113	0.00268	CcSEcCtD
Fingolimod—Hypotension—Cisplatin—testicular cancer	0.00113	0.00266	CcSEcCtD
Fingolimod—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.00111	0.00262	CcSEcCtD
Fingolimod—Cardiac arrest—Doxorubicin—testicular cancer	0.00111	0.00262	CcSEcCtD
Fingolimod—Infection—Etoposide—testicular cancer	0.0011	0.00259	CcSEcCtD
Fingolimod—Asthenia—Dactinomycin—testicular cancer	0.00109	0.00259	CcSEcCtD
Fingolimod—Influenza—Epirubicin—testicular cancer	0.00109	0.00257	CcSEcCtD
Fingolimod—Paraesthesia—Cisplatin—testicular cancer	0.00108	0.00256	CcSEcCtD
Fingolimod—Liver function test abnormal—Doxorubicin—testicular cancer	0.00108	0.00254	CcSEcCtD
Fingolimod—Dyspnoea—Cisplatin—testicular cancer	0.00107	0.00254	CcSEcCtD
Fingolimod—Skin disorder—Etoposide—testicular cancer	0.00107	0.00253	CcSEcCtD
Fingolimod—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.00105	0.00248	CcSEcCtD
Fingolimod—Bronchitis—Epirubicin—testicular cancer	0.00105	0.00247	CcSEcCtD
Fingolimod—Diarrhoea—Dactinomycin—testicular cancer	0.00104	0.00247	CcSEcCtD
Fingolimod—Pneumonia—Methotrexate—testicular cancer	0.00104	0.00246	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00104	0.00246	CcSEcCtD
Fingolimod—Infestation NOS—Methotrexate—testicular cancer	0.00104	0.00245	CcSEcCtD
Fingolimod—Infestation—Methotrexate—testicular cancer	0.00104	0.00245	CcSEcCtD
Fingolimod—Depression—Methotrexate—testicular cancer	0.00103	0.00244	CcSEcCtD
Fingolimod—Hypotension—Etoposide—testicular cancer	0.00103	0.00244	CcSEcCtD
Fingolimod—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.00103	0.00243	CcSEcCtD
Fingolimod—Influenza—Doxorubicin—testicular cancer	0.00101	0.00238	CcSEcCtD
Fingolimod—Asthenia—Ifosfamide—testicular cancer	0.001	0.00237	CcSEcCtD
Fingolimod—Paraesthesia—Etoposide—testicular cancer	0.000991	0.00234	CcSEcCtD
Fingolimod—Pruritus—Ifosfamide—testicular cancer	0.000989	0.00234	CcSEcCtD
Fingolimod—Weight decreased—Epirubicin—testicular cancer	0.000984	0.00233	CcSEcCtD
Fingolimod—Dyspnoea—Etoposide—testicular cancer	0.000984	0.00233	CcSEcCtD
Fingolimod—Pneumonia—Epirubicin—testicular cancer	0.000976	0.00231	CcSEcCtD
Fingolimod—Infestation NOS—Epirubicin—testicular cancer	0.00097	0.00229	CcSEcCtD
Fingolimod—Infestation—Epirubicin—testicular cancer	0.00097	0.00229	CcSEcCtD
Fingolimod—Bronchitis—Doxorubicin—testicular cancer	0.000968	0.00229	CcSEcCtD
Fingolimod—Diarrhoea—Ifosfamide—testicular cancer	0.000956	0.00226	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Etoposide—testicular cancer	0.000953	0.00225	CcSEcCtD
Fingolimod—Fatigue—Etoposide—testicular cancer	0.000952	0.00225	CcSEcCtD
Fingolimod—Dizziness—Ifosfamide—testicular cancer	0.000924	0.00218	CcSEcCtD
Fingolimod—CYP4F12—Metabolism—HPGDS—testicular cancer	0.000916	0.00754	CbGpPWpGaD
Fingolimod—Weight decreased—Doxorubicin—testicular cancer	0.000911	0.00215	CcSEcCtD
Fingolimod—Sinusitis—Epirubicin—testicular cancer	0.00091	0.00215	CcSEcCtD
Fingolimod—Pneumonia—Doxorubicin—testicular cancer	0.000903	0.00213	CcSEcCtD
Fingolimod—Infestation NOS—Doxorubicin—testicular cancer	0.000898	0.00212	CcSEcCtD
Fingolimod—Infestation—Doxorubicin—testicular cancer	0.000898	0.00212	CcSEcCtD
Fingolimod—Bradycardia—Epirubicin—testicular cancer	0.000887	0.00209	CcSEcCtD
Fingolimod—Eye disorder—Methotrexate—testicular cancer	0.00087	0.00205	CcSEcCtD
Fingolimod—Asthenia—Cisplatin—testicular cancer	0.000864	0.00204	CcSEcCtD
Fingolimod—Cardiac disorder—Methotrexate—testicular cancer	0.000864	0.00204	CcSEcCtD
Fingolimod—Connective tissue disorder—Epirubicin—testicular cancer	0.000856	0.00202	CcSEcCtD
Fingolimod—Angiopathy—Methotrexate—testicular cancer	0.000844	0.002	CcSEcCtD
Fingolimod—Sinusitis—Doxorubicin—testicular cancer	0.000842	0.00199	CcSEcCtD
Fingolimod—Mediastinal disorder—Methotrexate—testicular cancer	0.000839	0.00198	CcSEcCtD
Fingolimod—Diarrhoea—Cisplatin—testicular cancer	0.000824	0.00195	CcSEcCtD
Fingolimod—Alopecia—Methotrexate—testicular cancer	0.000822	0.00194	CcSEcCtD
Fingolimod—Bradycardia—Doxorubicin—testicular cancer	0.00082	0.00194	CcSEcCtD
Fingolimod—Mental disorder—Methotrexate—testicular cancer	0.000815	0.00193	CcSEcCtD
Fingolimod—Eye disorder—Epirubicin—testicular cancer	0.000814	0.00192	CcSEcCtD
Fingolimod—Cardiac disorder—Epirubicin—testicular cancer	0.000808	0.00191	CcSEcCtD
Fingolimod—Asthenia—Etoposide—testicular cancer	0.000792	0.00187	CcSEcCtD
Fingolimod—Connective tissue disorder—Doxorubicin—testicular cancer	0.000792	0.00187	CcSEcCtD
Fingolimod—CYP4F2—Metabolism—HPGDS—testicular cancer	0.000791	0.00651	CbGpPWpGaD
Fingolimod—Angiopathy—Epirubicin—testicular cancer	0.00079	0.00187	CcSEcCtD
Fingolimod—Mediastinal disorder—Epirubicin—testicular cancer	0.000785	0.00185	CcSEcCtD
Fingolimod—Back pain—Methotrexate—testicular cancer	0.000784	0.00185	CcSEcCtD
Fingolimod—Pruritus—Etoposide—testicular cancer	0.000781	0.00185	CcSEcCtD
Fingolimod—Alopecia—Epirubicin—testicular cancer	0.00077	0.00182	CcSEcCtD
Fingolimod—Vision blurred—Methotrexate—testicular cancer	0.000763	0.0018	CcSEcCtD
Fingolimod—Mental disorder—Epirubicin—testicular cancer	0.000763	0.0018	CcSEcCtD
Fingolimod—Diarrhoea—Etoposide—testicular cancer	0.000755	0.00178	CcSEcCtD
Fingolimod—Eye disorder—Doxorubicin—testicular cancer	0.000753	0.00178	CcSEcCtD
Fingolimod—Cardiac disorder—Doxorubicin—testicular cancer	0.000748	0.00177	CcSEcCtD
Fingolimod—Back pain—Epirubicin—testicular cancer	0.000733	0.00173	CcSEcCtD
Fingolimod—Angiopathy—Doxorubicin—testicular cancer	0.000731	0.00173	CcSEcCtD
Fingolimod—Dizziness—Etoposide—testicular cancer	0.00073	0.00172	CcSEcCtD
Fingolimod—Mediastinal disorder—Doxorubicin—testicular cancer	0.000726	0.00172	CcSEcCtD
Fingolimod—Leukopenia—Methotrexate—testicular cancer	0.000725	0.00171	CcSEcCtD
Fingolimod—Vision blurred—Epirubicin—testicular cancer	0.000714	0.00169	CcSEcCtD
Fingolimod—Alopecia—Doxorubicin—testicular cancer	0.000712	0.00168	CcSEcCtD
Fingolimod—Cough—Methotrexate—testicular cancer	0.000707	0.00167	CcSEcCtD
Fingolimod—Mental disorder—Doxorubicin—testicular cancer	0.000706	0.00167	CcSEcCtD
Fingolimod—Headache—Etoposide—testicular cancer	0.000691	0.00163	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000685	0.00162	CcSEcCtD
Fingolimod—SPHK1—Metabolism—HPGDS—testicular cancer	0.00068	0.00559	CbGpPWpGaD
Fingolimod—Leukopenia—Epirubicin—testicular cancer	0.000679	0.0016	CcSEcCtD
Fingolimod—Back pain—Doxorubicin—testicular cancer	0.000679	0.0016	CcSEcCtD
Fingolimod—Palpitations—Epirubicin—testicular cancer	0.00067	0.00158	CcSEcCtD
Fingolimod—CYP4F12—Metabolism—STK11—testicular cancer	0.000666	0.00548	CbGpPWpGaD
Fingolimod—Cough—Epirubicin—testicular cancer	0.000662	0.00156	CcSEcCtD
Fingolimod—Vision blurred—Doxorubicin—testicular cancer	0.000661	0.00156	CcSEcCtD
Fingolimod—Infection—Methotrexate—testicular cancer	0.000657	0.00155	CcSEcCtD
Fingolimod—Hypertension—Epirubicin—testicular cancer	0.000655	0.00155	CcSEcCtD
Fingolimod—CYP2E1—Biological oxidations—HPGDS—testicular cancer	0.000652	0.00537	CbGpPWpGaD
Fingolimod—Nervous system disorder—Methotrexate—testicular cancer	0.000648	0.00153	CcSEcCtD
Fingolimod—Skin disorder—Methotrexate—testicular cancer	0.000642	0.00152	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000641	0.00151	CcSEcCtD
Fingolimod—Leukopenia—Doxorubicin—testicular cancer	0.000628	0.00148	CcSEcCtD
Fingolimod—Palpitations—Doxorubicin—testicular cancer	0.00062	0.00146	CcSEcCtD
Fingolimod—Hypotension—Methotrexate—testicular cancer	0.000618	0.00146	CcSEcCtD
Fingolimod—Infection—Epirubicin—testicular cancer	0.000615	0.00145	CcSEcCtD
Fingolimod—Cough—Doxorubicin—testicular cancer	0.000612	0.00145	CcSEcCtD
Fingolimod—Nervous system disorder—Epirubicin—testicular cancer	0.000607	0.00143	CcSEcCtD
Fingolimod—Hypertension—Doxorubicin—testicular cancer	0.000606	0.00143	CcSEcCtD
Fingolimod—Skin disorder—Epirubicin—testicular cancer	0.000601	0.00142	CcSEcCtD
Fingolimod—Paraesthesia—Methotrexate—testicular cancer	0.000594	0.0014	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000593	0.0014	CcSEcCtD
Fingolimod—Dyspnoea—Methotrexate—testicular cancer	0.000589	0.00139	CcSEcCtD
Fingolimod—Hypotension—Epirubicin—testicular cancer	0.000578	0.00137	CcSEcCtD
Fingolimod—CYP4F2—Metabolism—STK11—testicular cancer	0.000575	0.00473	CbGpPWpGaD
Fingolimod—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000571	0.00135	CcSEcCtD
Fingolimod—Fatigue—Methotrexate—testicular cancer	0.00057	0.00135	CcSEcCtD
Fingolimod—Infection—Doxorubicin—testicular cancer	0.000569	0.00134	CcSEcCtD
Fingolimod—Nervous system disorder—Doxorubicin—testicular cancer	0.000561	0.00133	CcSEcCtD
Fingolimod—Skin disorder—Doxorubicin—testicular cancer	0.000556	0.00131	CcSEcCtD
Fingolimod—Paraesthesia—Epirubicin—testicular cancer	0.000556	0.00131	CcSEcCtD
Fingolimod—Dyspnoea—Epirubicin—testicular cancer	0.000552	0.0013	CcSEcCtD
Fingolimod—S1PR4—Signaling Pathways—H2AFZ—testicular cancer	0.000537	0.00442	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism of proteins—MMP2—testicular cancer	0.000536	0.00441	CbGpPWpGaD
Fingolimod—Hypotension—Doxorubicin—testicular cancer	0.000535	0.00126	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000534	0.00126	CcSEcCtD
Fingolimod—S1PR4—Signaling Pathways—STK11—testicular cancer	0.000534	0.00439	CbGpPWpGaD
Fingolimod—Fatigue—Epirubicin—testicular cancer	0.000533	0.00126	CcSEcCtD
Fingolimod—S1PR3—Signaling Pathways—H2AFZ—testicular cancer	0.000517	0.00425	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—H2AFZ—testicular cancer	0.000517	0.00425	CbGpPWpGaD
Fingolimod—Paraesthesia—Doxorubicin—testicular cancer	0.000514	0.00121	CcSEcCtD
Fingolimod—S1PR3—Signaling Pathways—STK11—testicular cancer	0.000514	0.00423	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—STK11—testicular cancer	0.000514	0.00423	CbGpPWpGaD
Fingolimod—Dyspnoea—Doxorubicin—testicular cancer	0.00051	0.00121	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000494	0.00117	CcSEcCtD
Fingolimod—S1PR4—Signaling Pathways—KITLG—testicular cancer	0.000494	0.00406	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism—STK11—testicular cancer	0.000494	0.00406	CbGpPWpGaD
Fingolimod—Fatigue—Doxorubicin—testicular cancer	0.000494	0.00117	CcSEcCtD
Fingolimod—S1PR5—Signaling Pathways—KITLG—testicular cancer	0.000475	0.00391	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—KITLG—testicular cancer	0.000475	0.00391	CbGpPWpGaD
Fingolimod—Asthenia—Methotrexate—testicular cancer	0.000474	0.00112	CcSEcCtD
Fingolimod—S1PR1—Signaling Pathways—H2AFZ—testicular cancer	0.000469	0.00386	CbGpPWpGaD
Fingolimod—Pruritus—Methotrexate—testicular cancer	0.000468	0.00111	CcSEcCtD
Fingolimod—S1PR1—Signaling Pathways—STK11—testicular cancer	0.000466	0.00384	CbGpPWpGaD
Fingolimod—CYP2D6—Biological oxidations—HPGDS—testicular cancer	0.000463	0.00381	CbGpPWpGaD
Fingolimod—Diarrhoea—Methotrexate—testicular cancer	0.000452	0.00107	CcSEcCtD
Fingolimod—Asthenia—Epirubicin—testicular cancer	0.000444	0.00105	CcSEcCtD
Fingolimod—Pruritus—Epirubicin—testicular cancer	0.000438	0.00103	CcSEcCtD
Fingolimod—Dizziness—Methotrexate—testicular cancer	0.000437	0.00103	CcSEcCtD
Fingolimod—S1PR1—Signaling Pathways—KITLG—testicular cancer	0.000432	0.00355	CbGpPWpGaD
Fingolimod—Diarrhoea—Epirubicin—testicular cancer	0.000423	0.001	CcSEcCtD
Fingolimod—SPHK1—Signaling Pathways—H2AFZ—testicular cancer	0.000415	0.00342	CbGpPWpGaD
Fingolimod—Headache—Methotrexate—testicular cancer	0.000414	0.000979	CcSEcCtD
Fingolimod—SPHK1—Signaling Pathways—STK11—testicular cancer	0.000413	0.0034	CbGpPWpGaD
Fingolimod—Asthenia—Doxorubicin—testicular cancer	0.000411	0.000971	CcSEcCtD
Fingolimod—Dizziness—Epirubicin—testicular cancer	0.000409	0.000967	CcSEcCtD
Fingolimod—Pruritus—Doxorubicin—testicular cancer	0.000405	0.000957	CcSEcCtD
Fingolimod—Diarrhoea—Doxorubicin—testicular cancer	0.000392	0.000926	CcSEcCtD
Fingolimod—Headache—Epirubicin—testicular cancer	0.000388	0.000916	CcSEcCtD
Fingolimod—SPHK1—Signaling Pathways—KITLG—testicular cancer	0.000382	0.00314	CbGpPWpGaD
Fingolimod—Dizziness—Doxorubicin—testicular cancer	0.000379	0.000895	CcSEcCtD
Fingolimod—S1PR4—Signaling Pathways—FGFR3—testicular cancer	0.000367	0.00302	CbGpPWpGaD
Fingolimod—Headache—Doxorubicin—testicular cancer	0.000359	0.000847	CcSEcCtD
Fingolimod—S1PR5—Signaling Pathways—FGFR3—testicular cancer	0.000353	0.00291	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—FGFR3—testicular cancer	0.000353	0.00291	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—KIT—testicular cancer	0.000337	0.00277	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—KIT—testicular cancer	0.000324	0.00267	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—KIT—testicular cancer	0.000324	0.00267	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—FGFR3—testicular cancer	0.000321	0.00264	CbGpPWpGaD
Fingolimod—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.000303	0.00249	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—KIT—testicular cancer	0.000295	0.00242	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—FGFR3—testicular cancer	0.000284	0.00234	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—KIT—testicular cancer	0.000261	0.00214	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—HPGDS—testicular cancer	0.000112	0.000918	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—STK11—testicular cancer	8.11e-05	0.000667	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—HPGDS—testicular cancer	7.92e-05	0.000651	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—STK11—testicular cancer	5.75e-05	0.000473	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—HPGDS—testicular cancer	5.18e-05	0.000426	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—STK11—testicular cancer	3.76e-05	0.000309	CbGpPWpGaD
